From these observations, we conjectured that the gene expression and functionality of CCR7+/RELB+/IRF1+ triple positive T cells could represent a distinctive feature of JIA, setting it apart from pSS and SLE and potentially serving as a therapeutic target for JIA. The gene discussed is RELB; the disease is systemic lupus erythematosus.